Could a targeted antibody boost chemo for kids with aggressive blood cancer?

NCT ID NCT01516580

Completed Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tested whether adding 6 doses of rituximab to standard chemotherapy improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. The study enrolled 482 high-risk patients aged 6 months to 18 years. The goal was to see if the combination extends event-free survival compared to chemotherapy alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rituximab (a targeted antibody) added to standard chemotherapy
What this could lead to: If successful, adding rituximab to chemotherapy could help more children with aggressive B-cell cancers stay cancer-free longer.
What could go wrong: This is a completed phase 3 trial, but results may not apply to all patients. Adding rituximab can increase infection risk and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGGRESSIVE MATURE B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma B-cell acute lymphoblastic leukemia B-cell neoplasm B-cell non-Hodgkin lymphoma Burkitt lymphoma diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NON-HODGKIN LYMPHOMA MATURE B-CELL LEUKEMIA BURKITT-TYPE

Contacts and locations

Locations

2nd Dept. of Pediatrics Semmelweis Univ.

Budapest, 1094, Hungary
Associazione Italiana di Ematologia ed Oncologia Pediatrica

Padova, 35128, Italy
Children Oncology Group Operations centres

Monrovia, Canada
Emma Children's Hospital

Amsterdam, 1105 AZ, Netherlands
Institut de Cancérologie Gustave roussy

Villejuif, 94805, France
Rectorat of Medical University

Wroclaw, Poland
Sociedad Española de Hematología y Oncología Pediátricas

Valencia, 46010, Spain
The University of Hong Kong (Clinical Trials Centre)

Hong Kong, China
University Hospitals Leuven

Leuven, 3000, Belgium
University of Birmingham

Birmingham, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.